Try our beta test site

Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified February 2017 by Gilead Sciences
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT03060447
First received: February 17, 2017
Last updated: NA
Last verified: February 2017
History: No changes posted
  Purpose
The primary objective of this study is to evaluate the safety and tolerability of a 10-dose regimen of GS-9620 in HIV-1 infected controllers on antiretroviral treatment (ART) and during analytical treatment interruption (ATI) following GS-9620 dosing.

Condition Intervention Phase
HIV-1 Infection
Drug: GS-9620
Drug: GS-9620 Placebo
Drug: ART
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers

Resource links provided by NLM:


Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Overall Safety Profile as Assessed by Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) and all Treatment-Emergent Adverse Events. [ Time Frame: Up to 45 weeks plus 30 days ]

Secondary Outcome Measures:
  • Virology: Changes in Plasma HIV-1 RNA and Cell Associated Viral RNA (CAVR) During the Dosing Period [ Time Frame: Up to 20 weeks ]
  • Virology: Changes in Peripheral Blood Mononuclear Cell (PBMC) HIV-1 Reservoir Between Baseline and Following GS-9620 Dosing [ Time Frame: Up to 45 weeks ]
  • Virology: Changes in Total CD4+ T Cell Reservoirs [ Time Frame: Up to 45 weeks ]
  • Virology: Time to Virologic Rebound and Plasma Viral Load Set-Point Following ATI [ Time Frame: Up to 25 weeks ]
  • Virology: Peak HIV-1 Viral Load During Period 2 [ Time Frame: Up to 25 weeks ]
  • Immunology/Pharmacodynamics: Changes in Serum/Plasma Cytokines [ Time Frame: Up to 45 weeks ]
  • Immunology/Pharmacodynamics: Changes in Plasma Kynurenine/ Tryptophan (K/T) [ Time Frame: Up to 45 weeks ]
  • Immunology/Pharmacodynamics: Changes in mRNA of Interferon-Stimulated Genes (ISGs) in Whole Blood [ Time Frame: Up to 45 weeks ]
  • Immunology/Pharmacodynamics: Changes in Immune cell Activation [ Time Frame: Up to 45 weeks ]
  • Immunology/Pharmacodynamics: Changes in HIV-1 Specific T cell Immune Responses [ Time Frame: Up to 45 weeks ]
  • Immunology/Pharmacodynamics: Changes in the Frequency of Regulatory T cells [ Time Frame: Up to 45 weeks ]
  • Immunology/Pharmacodynamics: Changes in the Quantity of HIV-Specific Antibodies [ Time Frame: Up to 45 weeks ]
  • Immunology/Pharmacodynamics: Changes in the Quality (Effector Functionality) of HIV-Specific Antibodies [ Time Frame: Up to 45 weeks ]
  • Immunology/Pharmacodynamics: Change in Plasma Inflammatory Markers [ Time Frame: Up to 45 weeks ]
  • Pharmacokinetic (PK) Parameter: Cmax of GS-9620 [ Time Frame: Up to 45 weeks ]
    Cmax is defined as maximum observed concentration of drug in plasma

  • PK Parameter: Ctau of GS-9620 [ Time Frame: Up to 45 weeks ]
    Ctau is defined as the observed drug concentration at the end of the dosing interval (tau)

  • PK Parameter: AUCtau of GS-9620 [ Time Frame: Up to 45 weeks ]
    AUCtau is defined as the area under the plasma concentration versus time curve over the dosing interval (tau)


Estimated Enrollment: 30
Anticipated Study Start Date: March 2017
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GS-9620

Period 1: Participants will receive up to 10 doses of GS-9620. Participants will continue to take their prescribed ART during this period.

Period 2: All participants will discontinue ART and be monitored for rebound in HIV-1 plasma viremia.

Drug: GS-9620
4 mg tablet administered orally once every 14 days
Drug: ART
ART regimens administered in accordance with their Prescribing Information
Experimental: GS-9620 placebo

Period 1: Participants will receive up to 10 doses of GS-9620 placebo. Participants will continue to take their prescribed ART during this period.

Period 2: All participants will discontinue ART and be monitored for rebound in HIV-1 plasma viremia.

Drug: GS-9620 Placebo
Tablet administered orally once every 14 days
Drug: ART
ART regimens administered in accordance with their Prescribing Information

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Plasma HIV-1 RNA levels <50 copies/mL at screening
  • Pre-ART Plasma HIV-1 RNA set point between 50 and ≤ 5,000 copies/mL measured within two years prior to ART initiation
  • On ART for ≥ 6 months prior to screening
  • Documented plasma HIV-1 RNA < 50 copies/mL for ≥ 6 months preceding the screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL). Unconfirmed virologic elevations of ≥ 50 copies/mL (transient detectable viremia, or "blip") prior to screening are acceptable.
  • No documented history of resistance to any components of the current ART regimen
  • Availability of a fully active alternative ART regimen, in the opinion of the Investigator, in the event of discontinuation of the current ART regimen with development of resistance.
  • Hemoglobin ≥ 11.5 g/dL (males) or ≥ 11 g/dL (females)
  • White Blood Cells ≥ 2,500 cells/μL
  • Platelets ≥ 125,000/mL
  • Absolute Neutrophil Counts ≥ 1000 cells/μL
  • CD4+ count ≥ 500 cells/μL
  • Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or bilirubin ≤ 2 × upper limit of normal (ULN)
  • Estimated glomerular filtration rate ≥ 60 mL/min
  • No autoimmune disease requiring on-going immunosuppression
  • No evidence of current hepatitis B virus (HBV) infection
  • No evidence of current hepatitis C virus (HCV) infection (positive anti-HCV antibody and negative HCV polymerase chain reaction (PCR) results are acceptable)
  • No documented history of pre-ART CD4 nadir < 200 cells/μL (unknown pre-ART CD4 nadir is acceptable)
  • No history of opportunistic illness indicative of stage 3 HIV
  • No acute febrile illness within 35 days prior to Pre-Baseline/ Day -13

Note: Other protocl defined Inclusion/Exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03060447

Locations
United States, California
Zuckerberg San Francisco General
San Francisco, California, United States, 94110
Sponsors and Collaborators
Gilead Sciences
Investigators
Study Director: Gilead Study Director Gilead Sciences
  More Information

Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT03060447     History of Changes
Other Study ID Numbers: GS-US-382-3961
Study First Received: February 17, 2017
Last Updated: February 17, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

ClinicalTrials.gov processed this record on March 30, 2017